HCPCS J1414 is officially defined as "Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose." HCPCS J1414 is referenced in 2 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J1414 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.